A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD9164 After Administration of Single and Multiple Ascending Doses for 13 Days in Healthy Male and Female Japanese Subjects

AstraZeneca1 site in 1 country27 target enrollmentMarch 2010

ConditionsHealthy

InterventionsAZD9164 Placebo

DrugsAZD9164 Placebo

Overview

Phase: Phase 1
Intervention: AZD9164
Conditions: Healthy
Sponsor: AstraZeneca
Enrollment: 27
Locations: 1
Primary Endpoint: Safety measurements (ECG's, Telemetry, Pulse, Blood Pressure, Safety Laboratory and Adverse Events)
Status: Terminated
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a single centre, Double blinded, Randomised, Placebo-controlled, Parallel group study to access the safety, tolerability, and pharmacokinetics of Inhaled AZD9164 after administration of single and Multiple Ascending doses in Japanese subjects.

Registry

clinicaltrials.gov

Start Date

March 2010

End Date

June 2010

Last Updated

15 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

AstraZeneca

Eligibility Criteria

Inclusion Criteria

•Healthy Japanese subjects with suitable veins for cannulation or repeated venipuncture
•Have a body mass index (BMI) between 18 and 27 kg/m2 and a body weight between 50 and 85 kg
•Male subjects should be willing to use barrier contraception ie, condoms with spermicide, from the first day of dosing until 3 months after the last dose of investigational product

Exclusion Criteria

•History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
•History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
•Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product

Arms & Interventions

1

AZD9164

Intervention: AZD9164

2

Intervention: Placebo

Outcomes

Primary Outcomes

Safety measurements (ECG's, Telemetry, Pulse, Blood Pressure, Safety Laboratory and Adverse Events)

Time Frame: Safety will be monitored continously and safety assessments will be made on several occasions throughout the whole study

Secondary Outcomes

To investigate the pharmacokinetics (PK) of AZD9164 following inhaled administration of single and multiple ascending doses, by assessment of the dose proportionality, the degree of accumulation and the time linearity(PK sampling during the residential period and intense PK sampling on day 1 and day 15 (up to 72 and 120 hours respectively))
To investigate pharmacodynamic (PD) effects of inhaled single and multiple ascending doses of AZD9164, by assessment of lung function(Spirometry during the residential stay on days 1, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15)